Skip to main content

Advertisement

Table 2 Cardiovascular events during follow-up by tertiles of plasma copeptin at baseline

From: Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes

  DIABHYCAR SURDIAGENE
No events Cardiovascular events No events Cardiovascular events
T1 873 (84.4%) 161 (15.6%) 339 (72.3%) 130 (27.7%)
T2 841 (81.3%) 193 (18.7%) 309 (65.9%) 160 (34.1%)
T3 808 (78.4%) 223 (21.6%) 246 (52.4) 223 (47.6%)
  1. Data expressed as number of cases and (%) by line. Hazards ratio (HR) computed by Cox proportional hazards survival regression analysis for tertiles of plasma copeptin, and for 1 unit of loge[copeptin]. Model 1: adjusted for sex, age, BMI, duration of diabetes, systolic blood pressure, arterial hypertension, HbA1c, total cholesterol, HDL-cholesterol, triglycerides, active tobacco smoking, and previous history of myocardial infarction at baseline. In DIABHYCAR, analysis was further adjusted for study treatment (randomization group in the original DIABHYCAR study: ramipril vs placebo) during follow-up. Model 2: model 1 plus adjustments for eGFR and UAC at baseline. p < 0.05 is significant
  HR (95% CI) p HR (95% CI) p
Model 1
 T3 vs T1 1.40 (1.13–1.72) 0.001 2.10 (1.68–2.64) < 0.0001
 T2 vs T1 1.28 (1.04–1.59) 0.02 1.46 (1.15–1.85) 0.002
 T3 vs T2 1.09 (0.90–1.33) 0.39 1.44 (1.18–1.78) 0.0005
 Loge[copeptin] 1.21 (1.06–1.37) 0.004 1.52 (1.37–1.67) < 0.0001
Model 2
 T3 vs T1 1.29 (1.04–1.59) 0.02 1.58 (1.23–2.04) 0.0004
 T2 vs T1 1.25 (1.01–1.54) 0.04 1.39 (1.10–1.77) 0.006
 T3 vs T2 1.03 (0.85–1.26) 0.75 1.14 (0.91–1.43) 0.27
 Loge[copeptin] 1.13 (0.99–1.29) 0.06 1.28 (1.12–1.46) 0.0003
  1. Data expressed as number of cases and (%) by line. Hazards ratio (HR) computed by Cox proportional hazards survival regression analysis for tertiles of plasma copeptin, and for 1 unit of loge[copeptin]. Model 1: adjusted for sex, age, BMI, duration of diabetes, systolic blood pressure, arterial hypertension, HbA1c, total cholesterol, HDL-cholesterol, triglycerides, active tobacco smoking, and previous history of myocardial infarction at baseline. In DIABHYCAR, analysis was further adjusted for study treatment (randomization group in the original DIABHYCAR study: ramipril vs placebo) during follow-up. Model 2: model 1 plus adjustments for eGFR and UAC at baseline. p < 0.05 is significant